NeoGenomics Announces New Directors

FORT MYERS, Fla., June 17, 2015 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ:  NEO), a leading provider of cancer-focused genetic testing services announced today that Alison L. Hannah, M.D. and Lynn A. Tetrault were elected to its Board of Directors at the Annual Meeting of Shareholders held on June 12, 2015. 

Dr. Hannah has over 25 years' experience in the development of investigational cancer chemotherapies.  Since 2000, she has served as a consultant to the pharmaceutical industry, working with over 20 companies with a focus on molecularly targeted therapy.  Prior to this, she worked as Senior Medical Director at SUGEN on various compounds, including Sutent® approved in kidney cancer, and Quintiles, a global Contract Research Organization.  Dr. Hannah specializes in clinical development strategy, and has filed over 30 Investigational New Drug applications for new molecular entities and 7 New Drug Applications.  She participates in Data Monitoring Committees, Scientific Advisory Boards and Independent Review Committees for clinical trials.  She has a bachelor's degree in biochemistry and immunology from Harvard University and her medical degree from the University of Saint Andrews.  She is a member of ASCO, AACR, ASH, ESMO and a Fellow with the Royal Society of Medicine.  At NeoGenomics, Dr. Hannah will serve as a member of the Compliance Committee.

Ms. Tetrault worked from 1993 to 2014 with AstraZeneca, PLC most recently as Executive Vice President HR and Corporate Affairs. At Astra Zeneca, Ms. Tetrault was responsible for all human resources strategy, talent management, executive compensation and related activities, internal and external communications, government affairs, corporate reputation and corporate social responsibility for the Company. She has an undergraduate degree from Princeton University and a J.D. from the University of Virginia Law School.  She is currently a consultant to various healthcare companies and serves as a director of Women's Way. At NeoGenomics, Ms. Tetrault will serve as the Chair of the Board's Nominating and Governance Committee, and a member of the Compensation Committee.

Douglas VanOort, Chairman and Chief Executive Officer, stated, "We are delighted to welcome Dr. Hannah and Ms. Tetrault to our Board.  Each of them brings a breadth of experience and valuable perspective to NeoGenomics as we meet the challenges and pursue the exciting opportunities ahead.  We are very pleased to have them join our team."     

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing.  Headquartered in Fort Myers, FL, NeoGenomics has laboratories in Nashville, TN, Irvine, Fresno and West Sacramento CA, Tampa and Fort Myers, FL.  NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com.   

Interested parties can also access investor relations material from Hawk Associates at http://www.hawkassociates.com  or [email protected].

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements.  These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements.  Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.

SOURCE NeoGenomics, Inc.

Related Links

http://www.neogenomics.org